Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30170977 | 1.00 | CA2 (0.47) | CA2MEN1KMT2AESR1GAA | |
| SCHEMBL4218710 | 0.89 | MEN1 (0.41) | CA2MEN1KMT2AESR1GAA | |
| SCHEMBL6629103 | 0.85 | CA2 (0.44) | CA2MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL4622281 | 0.85 | CA2 (0.44) | CA2MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL4620614 | 0.82 | DRD2 (0.43) | CA2MEN1KMT2AESR1GAA | |
| SCHEMBL4619378 | 0.82 | DRD2 (0.43) | CA2MEN1KMT2AESR1GAA | |
| SCHEMBL4621894 | 0.82 | DRD2 (0.43) | CA2MEN1KMT2AESR1GAA | |
| SCHEMBL30170903 | 0.82 | DRD2 (0.43) | CA2MEN1KMT2AESR1GAA | |
| SCHEMBL4621704 | 0.81 | CA2 (0.43) | CA2MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL4621993 | 0.81 | CA2 (0.43) | CA2MEN1KMT2AGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080182891-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182891-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-07-31 | — | — | US | disclosed |
| US-7365095-B2 | Chromane and chromene derivatives and uses thereof | WYETH (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365095-B2 | Chromane and chromene derivatives and uses thereof | WYETH (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1874756-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | Wyeth (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20060258714-A1 | Chromane and chromene derivatives and uses thereof | WYETH (US) | 2006-11-16 | — | — | US | disclosed |
| WO-2006116165-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182891-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | HTR1A, HTR2C, CHRM1 | CA2 2235/4885MEN1 1380/4885KMT2A 2030/4885 |
| US-20060258714-A1 | Chromane and chromene derivatives and uses thereof | HTR1A, HTR2C, CHRM1 | CA2 2235/4885MEN1 1380/4885KMT2A 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.